Sprout Health Review: GLP-1 Pricing and the FDA Letter

Sprout Health is a GLP-1 weight-loss telehealth company, and this is a site about sleep peptides — so the first question is why it is here at all. The answer is obstructive sleep apnea. Weight loss is the intervention with the strongest effect on OSA severity, one GLP-1 now carries an FDA approval for it, and readers arriving at our GLP-1 and sleep apnea page reasonably want to know where the medication is actually sold. Sprout is one of the places we surface. The FDA issued it a warning letter in September 2025, and that belongs on the same page as everything else we say about the company.

The FDA warning letter

The FDA issued a warning letter to Sprout Health Partners LLC dba Sprout Health in September 2025. We say so here, and on every surface of this site that profiles the company, because we earn a commission when a reader starts care through some of the links on this site and a reader is entitled to know the letter exists before they decide.

We are not paraphrasing what the agency alleged. A warning letter is a formal public document, and the version that counts is the FDA's own wording rather than a summary written by a site with a commercial interest. It is searchable by company name in the FDA's warning-letter database¹ — read it there before you decide.

How we are treating it: Sprout stays listed and its links stay live. A warning letter is a compliance action, not a determination that a company may not operate, and quietly deleting a provider from a comparison page does not protect the reader looking at that page — it just makes the page less honest than the market it claims to describe. What we owe instead is the disclosure, in every place the company appears.

What Sprout charges

Sprout publishes four prices on the lander, which is more transparency than a quiz-gated competitor gives you:

• •Compounded semaglutide — from $149/month
• •Compounded tirzepatide — from $199/month
• •Wegovy® — from $1,579/month
• •Zepbound® — from $1,249/month

The gap between the compounded and brand-name columns is the whole decision in miniature. The compounded products are not FDA-approved and are not the same thing as Wegovy or Zepbound; the branded ones are the drugs the trials were run on. Semaglutide and tirzepatide both have large randomised weight-loss trials behind them²³ — those trials studied the branded products, and that distinction is what the ten-fold price difference is really about.

For readers whose interest here is sleep rather than weight: tirzepatide is the molecule with the sleep-apnea approval, which puts the $199 compounded tier and the $1,249 Zepbound tier on either side of a genuinely consequential choice. Our GLP-1 and sleep apnea page works through what the trial actually showed.

You pay before you are evaluated

This is the detail worth knowing in advance, and Sprout states it openly in its own FAQ: the short quiz is a pre-qualification, and the detailed medical questionnaire comes after the purchase. Your assigned clinician reviews that questionnaire, and only then is a prescription issued and the medication shipped. If the clinician decides treatment is not appropriate, the order is cancelled and refunded.

That is a legitimate and reasonably common structure, and the refund commitment is stated plainly. But it does mean the sequence is pay, then be assessed — not assessed, then pay — and anyone who dislikes having money in a company's hands during a clinical decision should know that before starting rather than after. Shipping is quoted at three to seven business days once the prescription is issued, from a US pharmacy in refrigerated packaging, and plans renew monthly on the same date.

Reading the claims carefully

Sprout advertises that members self-reported losing an average of 6.4% of body weight in their first 12 weeks, and — to its credit — labels it as self-reported with results varying. Treat that as what it is: a company-collected, self-reported figure from its own customers, not a trial endpoint. It is not comparable to the numbers from the randomised trials that support these molecules, and Sprout does not claim it is.

The testimonials on the page are first-party, hosted by Sprout and marked "Verified Customer" by Sprout. That is not the same as an independent review platform, and it is worth weighing accordingly. The site also carries a LegitScript certification badge and states that its clinicians are US-licensed.

One promise is specific enough to hold the company to: for patients transferring in from another provider, Sprout advertises "transparent monthly pricing, locked in" and "no price hikes", with a free transition consult and the same starting dose. If you switch on the strength of that, get the locked-in figure confirmed in writing for the dose you are on.

Where this fits on a sleep site

Be clear about what a GLP-1 is and is not doing for your sleep. If your sleep is broken by obstructive apnea, weight loss addresses the mechanism; a growth-hormone peptide does not, which is the argument we make at length in sermorelin and sleep apnea. If your sleep is broken for other reasons, a GLP-1 is not the tool, and the honest comparison of the two categories is in sermorelin and semaglutide. Neither is a substitute for a diagnosis: if you snore, gasp, or wake unrefreshed, get tested before you buy anything.

Bottom line

Sprout publishes its prices — including the brand-name ones most compounders leave off the page — has a real branded lane alongside the compounded one, and states its refund position clearly. It also received an FDA warning letter in September 2025, sequences payment ahead of the full clinical assessment, and leans on self-reported outcomes and first-party testimonials. Read the letter in the FDA's own database, decide with the branded-versus-compounded distinction firmly in mind, and if sleep apnea is the reason you are here, get the diagnosis first.